Exclusive interview with Histogen Inc. CEO and Founder Dr. Gail Naughton:
HSC Trial Shows Continued Significant Hair Growth at One Year Follow-up
Histogen to present one year clinical trial data at Society for Investigative Dermatology Annual Meeting
SAN DIEGO, April 13, 2010 – Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced the one year data findings of its Hair Stimulating Complex (HSC) pilot clinical trial. Statistically significant new hair growth was seen in HSC-treated subjects at this follow-up timepoint, one year after their single treatment with HSC. Read more ›
Histogen, Inc., the regenerative medicine company that develops products derived from newborn fibroblasts, is apparently seeing some impressive results after conducting preliminary clinical trials of their HSC human hair regrowth product. These results were announced at this year’s ISHRS conference that took place in Amsterdam this past July. The buzz on the street is that Histogen just might be onto something big!



